Anika Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Anika Therapeutics

04/03/2023 24:05

* Anika Therapeutics Inc  ANIK.OQ   ANIK.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The Bedford Massachusetts-based  company is expected to
report 
a 5.3% increase in revenue to $37.705 million from $35.82
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Anika Therapeutics
Inc is
for a loss of 24 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Anika
Therapeutics Inc is $31​, below​ its last closing price
of $31.59. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.25       -0.25      -0.15     Beat    40
 Jun. 30 2022  -0.21       -0.23      -0.20     Beat    11.8
 Mar. 31 2022  -0.37       -0.36      -0.20     Beat    45.2​
 Dec. 31 2021  -0.29       -0.25      -0.40     Missed  -58.4
 ​​Sep.        -0.21       -0.21      0.04      Beat    119
 30 2021                                                
 Jun. 30 2021  -0.15       -0.15      0.45      Beat    406.8​
 Mar. 31 2021  -0.13       -0.12      0.20      Beat    260
 Dec. 31 2020  -0.10       0.14       0.12      Missed  -14.3
 This summary was machine generated March 4 at 00:05 GMT.  All
figures in US dollars  unless otherwise stated